Aligos Therapeutics獲180萬歐元VLAIO撥款，用於推進慢性乙肝研究

StephenW

Aligos Therapeutics is awarded €1.8M VLAIO grant to advance chronic hepatitis B research
Email Print Friendly Share
November 12, 2020 08:00 ET | Source: Aligos Therapeutics

SOUTH SAN FRANCISCO, Calif. and LEUVEN, Belgium, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that its Belgian subsidiary Aligos Belgium BV has been awarded a €1.8M grant by the Flemish Agency for Innovation and Entrepreneurship (VLAIO) to support a nonclinical research project related to combination therapy for Hepatitis B at Aligos (CoHeBA).

“CoHeBA aims to elucidate the mechanism of action of the therapeutic candidates for chronic hepatitis B (CHB) currently in development at Aligos,” said Yannick Debing, Ph.D., principal scientist and lead on the project application. “The support from VLAIO will allow us to collaborate with some of the most esteemed leaders in the hepatitis B field to identify how Aligos’ CHB assets target components of the hepatitis B virus life cycle. Developing a greater understanding of the candidates’ mechanism of action will empower our scientific team to develop pharmacologically best-in-class therapies.”

The three-year project will include collaborations with the laboratories of Prof. Jan Paeshuyse (KU Leuven, Belgium), Profs. Stephen Locarnini and Hans Netter (VIDRL, Melbourne, Australia), Profs. Patrick Kennedy and Upkar Gill (Queen Mary University London, United Kingdom), and Profs. Thomas Baumert and Eloi Verrier (INSERM U1110, University of Strasbourg, France).

“Our team at Aligos Belgium BV contributes greatly to our success in discovering potential therapies for an infection that affects hundreds of millions of people, increasing their risk of end-stage liver disease,” said Lawrence Blatt, Ph.D., MBA, Chief Executive Officer of Aligos. “We expect that the outcomes of this project will help us design the most promising combination therapies and next-generation therapeutics for those patients.”

About Chronic Hepatitis B (CHB)

CHB is a major cause of chronic liver disease that affects over 290 million people worldwide. Serious complications of CHB include cirrhosis and liver cancer, which are associated with significant mortality. Approximately 900,000 people died from CHB-related causes in 2015 alone and the mortality rate associated with HBV-related liver cancer continues to increase. Although current standard of care for patients with CHB is effective in suppressing HBV, it is associated with very low rates of functional cure, which is the goal for future CHB treatments.

About Aligos

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

About the Agency for Innovation & Entrepreneurship
(Agentschap Innoveren & Ondernemen, VLAIO) – www.vlaio.be

This project is supported by the Agency for Innovation & Entrepreneurship, the point of contact of the Flemish Government for all entrepreneurs in Flanders. VLAIO stimulates and supports innovation and entrepreneurship and contributes to a favorable entrepreneurial climate, in collaboration with many partners.

StephenW

Aligos Therapeutics获180万欧元VLAIO拨款，用于推进慢性乙肝研究
电子邮件打印友好分享
东部时间2020年11月12日08:00 |资料来源：Aligos Therapeutics

加利福尼亚州南旧金山和比利时鲁汶，2020年11月12日（全球新闻）-Aligos Therapeutics，Inc.（纳斯达克股票代码：ALGS）是一家临床阶段的生物制药公司，致力于开发新型疗法以解决病毒中未满足的医疗需求和肝脏疾病，今天宣布其比利时子公司Aligos Belgium BV已获得法兰德斯创新与创业署（VLAIO）的180万欧元拨款，以支持与Aligos乙肝联合疗法相关的非临床研究项目（CoHeBA） 。

“ CoHeBA旨在阐明Aligos目前正在开发的慢性乙型肝炎（CHB）治疗候选药物的作用机制，”该项目申请书的首席科学家和负责人Yannick Debing博士说。 “ VLAIO的支持将使我们能够与乙肝领域的一些最受尊敬的领导者合作，以确定Aligos的CHB资产如何针对乙肝病毒生命周期的组成部分。对候选人的作用机制有更深入的了解，将使我们的科学团队有能力开发出药理学上一流的疗法。”

这个为期三年的项目将包括与Jan Paeshuyse教授（比利时鲁汶大学），Professor教授实验室的合作。 Stephen Locarnini和Hans Netter（VIDRL，澳大利亚墨尔本），教授。帕特里克·肯尼迪（Patrick Kennedy）和Upkar Gill（英国伦敦玛丽大学），以及教授。 Thomas Baumert和Eloi Verrier（法国斯特拉斯堡大学，INSERM U1110）。

“我们在Aligos Belgium BV的团队为发现可能影响数百万人的感染，增加其罹患晚期肝病的风险的潜在疗法做出了巨大的贡献，” MBA博士首席劳伦斯·布拉特（Lawrence Blatt）说Aligos执行官。 “我们希望该项目的成果将有助于我们为这些患者设计最有前途的联合疗法和下一代疗法。”

关于慢性乙型肝炎（CHB）

CHB是慢性肝病的主要原因，全世界有超过2.9亿人受到感染。 CHB的严重并发症包括肝硬化和肝癌，这与死亡率高相关。仅在2015年，约有90万人死于与CHB相关的原因，与HBV相关的肝癌相关的死亡率继续上升。尽管当前针对CHB患者的护理标准可有效抑制HBV，但它与极低的功能治愈率相关，这是未来CHB治疗的目标。

关于阿里戈斯

Aligos Therapeutics，Inc.是一家临床阶段生物制药公司，成立于2018年，其使命是成为病毒感染和肝病治疗的全球领导者。 Aligos致力于开发针对慢性乙型肝炎（CHB）和冠状病毒的针对性抗病毒疗法，并利用其在肝脏疾病方面的专业知识来开发针对非酒精性脂肪性肝炎（NASH）的针对性疗法。 Aligos的策略是利用其员工在肝脏疾病（尤其是病毒性肝炎）方面拥有的深厚专业知识和数十年的药物开发经验，来快速推进其潜在最佳分子产品的开发。

关于创新创业机构
（VLAIO，Agentschap Innoveren＆Ondernemen）– www.vlaio.be

该项目由佛兰德政府与法兰德斯所有企业家的联络点创新与创业署提供支持。 VLAIO与许多合作伙伴合作，激发并支持创新和创业精神，并为营造良好的创业氛围做出了贡献。